Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 25,315 followers.

lncRNA546 urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone https://t.co/mFkZIm3elQ https://t.co/EsrTi2LkTO

12 Sep 2022

Reply Repost Favourite

New article: Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone https://t.co/UFjE7uHitp #prostatecancer #oncology https://t.co/9OEq3uED2L

29 Aug 2022

Reply Repost Favourite

Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone: Background and objectives Prostate specific antigen (PSA) is currently #oncology… https://t.co/Ji

12 Aug 2022

Reply Repost Favourite

New research: Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone: Background and objectives Prostate specific antigen (PSA) is currently… https://t.c

12 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.